Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers

• Published in: Psychopharmacology 2013-11, Vol.230 (2), p.227-234
• Main Authors: Sato, Hirotoshi, Ito, Chihiro, Tashiro, Manabu, Hiraoka, Kotaro, Shibuya, Katsuhiko, Funaki, Yoshihito, Iwata, Ren, Matsuoka, Hiroo, Yanai, Kazuhiko
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Antidepressive Agents - administration & dosage; Antidepressive Agents - pharmacokinetics; Antidepressive Agents - pharmacology; Area Under Curve; Biomedical and Life Sciences; Biomedicine; Brain - metabolism; Chromatography, Liquid; Double-Blind Method; Doxepin; Fluvoxamine - administration & dosage; Fluvoxamine - pharmacokinetics; Fluvoxamine - pharmacology; Histamine H1 Antagonists - administration & dosage; Histamine H1 Antagonists - pharmacokinetics; Histamine H1 Antagonists - pharmacology; Humans; Male; Mianserin - administration & dosage; Mianserin - analogs & derivatives; Mianserin - pharmacokinetics; Mianserin - pharmacology; Neurosciences; Original Investigation; Pharmacology/Toxicology; Positron-Emission Tomography - methods; Psychiatry; Receptors, Histamine H1 - metabolism; Sleep Stages - drug effects; Tandem Mass Spectrometry; Young Adult
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/s00213-013-3146-1

Rationale Histamine H 1 antagonists have hypnotic, appetite-promoting, and sedative effects. The affinities of various antidepressants for histamine receptors have only been partially determined in vitro and animal study. Positron emission tomography (PET) can clarify the in vivo dynamics of antidepressants at histamine receptors. Objectives We performed human PET imaging with [ 11 C]doxepin, a selective PET ligand of the histamine H 1 receptor (H 1 R), to study the in vivo affinities of fluvoxamine and mirtazapine for the H 1 R. Methods The subjects were five male healthy Japanese volunteers. We performed cross-randomized PET imaging after single oral administration of fluvoxamine (25 mg), mirtazapine (15 mg), or placebo. PET data were analyzed by region-of-interest and voxel-by-voxel analysis. We concurrently measured plasma drug concentrations, using liquid chromatography/tandem mass spectrometry and subjective sleepiness. Results The binding potential ratio of mirtazapine in brain cortex was significantly lower than that of fluvoxamine or placebo. Fluvoxamine did not occupy the H 1 R, whereas H 1 R occupancy (H 1 RO) of mirtazapine reached 80–90 % in the cerebral neocortex. In the voxel-by-voxel analysis, the binding potential of mirtazapine was significantly lower than placebo in the dorsolateral prefrontal cortex, lateral temporal cortex, anterior cingulate gyrus, and posterior cingulate gyrus. The H 1 RO of mirtazapine depended on the plasma drug concentration (AUC 0–180 min ) and was related to subjective sleepiness. Conclusions Our results demonstrate a low affinity of fluvoxamine and a very high affinity of mirtazapine for the human brain H 1 R in vivo. This study provides a basis for investigating the efficacy of new-generation antidepressants in central histamine systems.